Tauklarify imaging is a brain PET scan that shows tau tangles, clumps of tau protein that form inside brain cells in Alzheimer's. According to Lantheus, the FDA approved it on Aug.
14, 2026 for adults with cognitive impairment being evaluated for Alzheimer's FDA approval announcement. Younger-onset Alzheimer's means diagnosis before age 65, often in the 40s-50s while people are working or parenting. For these families, a tau result can sharpen the diagnostic picture and help focus talks about care, work, and family plans.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the scan add?
- How well do readers agree?
- What are the dose, side effects, and limits?
- What should younger-onset families ask next?
What does the scan add?
Tauklarify uses an F-18 tracer that sticks to clumped tau and lights up on PET. It complements amyloid PET and memory testing by showing where a person may stand in Alzheimer's progression. A positive scan points to tau tangle pathology tied to Alzheimer's.
A negative scan points away from that pattern. Neither result stands alone as a diagnosis. For younger adults, this context matters because memory change has many causes. A tau PET can help the care team weigh Alzheimer's against other conditions and choose next steps.
How well do readers agree?
Approval rested on two pivotal studies with five blinded readers scoring scans as positive or negative. According to NeurologyLive, positive agreement ranged from 68 percent to 88 percent and negative agreement from 93 percent to 99 percent against amyloid PET plus cognitive status NeurologyLive report. Agreement between readers was high, with Fleiss kappa values of 0.92 and 0.86.
That supports steady positive-versus-negative reads across centers. In practice, negative reads were more consistent than positive reads. Families should ask how the local team handles borderline or mixed results.
What are the dose, side effects, and limits?
The recommended dose is a single 185 MBq intravenous bolus given before imaging. In 1,734 subjects, the main effects were headache, nausea, injection-site reactions, dizziness, and abdominal discomfort.
Limits matter for decisions. According to Pharmacy Times, safety and effectiveness are not established for non-Alzheimer tauopathies, a negative scan does not rule out tau, a positive scan does not alone confirm it, and performance may be lower earlier in disease Pharmacy Times report.
- Ask what a positive or negative result would change in your care plan
- Ask about other causes of tau and how they are ruled out
- Ask about timing, since early disease may be harder to detect
What should younger-onset families ask next?
Most younger-onset cases are sporadic, yet the work and family stakes are high. Jobs, parenting, driving, finances, and future care often need attention at once. Tauklarify is the second FDA-approved tau PET tracer after Tauvid from 2020.
A 682-person head-to-head study found stronger discrimination of Alzheimer-related impairment with MK-6240 than with the older tracer. Use the scan as one piece of a full workup. Bring a symptom timeline, work impact notes, family history, medication list, and questions about support services to the follow-up visit.
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
